Gabanyuro Sustained-Release Tablet 150 mg (Pregabalin)

Adult dosage

This medication is administered once daily after the evening meal. It should be swallowed whole and not crushed, broken, or chewed. The starting dose may be 150 mg once daily and may be increased to a maximum of 600 mg once daily at weekly intervals based on individual patient response and tolerance. When discontinuing, dosage should be gradually reduced over at least a week's time.

This medication may increase the risk of suicidal thoughts and behaviors, so patients should be carefully monitored for signs of depression, mood changes, or abnormal behavior during treatment. Patients allergic to pregabalin or any ingredients in this medication should not use it. Diabetic patients may need to adjust the dosage of blood sugar control medication due to weight gain. If symptoms of angioedema occur, such as swelling of the face or around the mouth, discontinue use immediately and consult a healthcare professional. Elderly patients should take special care at the beginning of treatment due to the risk of falls or injury from dizziness or drowsiness. These symptoms should be reported to a healthcare professional, as blurred vision or vision changes may occur. Abrupt discontinuation of this medication may cause withdrawal symptoms such as insomnia, headache, nausea, and anxiety, so dosage should be gradually reduced according to a healthcare professional's instructions. Patients with a history of drug abuse may have a higher risk of abuse with this medication, thus caution is warranted. Patients with reduced kidney function may require dosage adjustments, and it should be administered cautiously to patients with severe heart failure. Concomitant use with opioid analgesics may increase the risk of central nervous system depression, so caution is advised. This medication should not be taken by pregnant women in early pregnancy due to the risk of congenital malformations in the fetus, and women of childbearing age should use effective contraception. Dizziness and drowsiness may occur during treatment, so it is advisable to avoid driving or operating hazardous machinery. Serious skin reactions may occur infrequently; if rashes or skin abnormalities appear, discontinue use immediately and consult a healthcare professional. In case of overdose, confusion, drowsiness, depression, seizures, etc., may occur, requiring immediate emergency treatment. This medication should be kept out of reach of children and should not be transferred to another container for safety.

Serious side effects

Urticaria, severe swelling (edema), cold sweat, severe rash with high fever, blisters, skin peeling, pain in the mucous membranes of the mouth/eyes, difficulty breathing or shortness of breath, asthma attacks, cough with accompanying fever leading to breathing difficulties, yellowing of the skin or eyes (jaundice), extreme lethargy, sudden and severe headache, thunderclap headache, seizures, confusion of consciousness, visual disturbances, paralysis, markedly reduced urine output, severe generalized swelling

Mild side effects

Dizziness, drowsiness, headache, confusion, somnolence, constipation, dyspepsia, nausea, dry mouth, vomiting, abdominal bloating, weight gain, increased blood levels of creatine phosphokinase, bradycardia, palpitations, blurred vision, itching, joint pain, hypoglycemia, nasopharyngitis, hypertension, snoring, epistaxis, cough, nasal congestion, rhinitis, throat tightness, nasal dryness, decreased oral sensation, excessive salivation, ascites, dysphagia, pancreatitis, sweating, papular rash

This medication should be stored in a tightly closed container to prevent air and moisture from entering. The storage temperature should be maintained at room temperature between 1 and 30 degrees Celsius.

Appearance

White to slightly yellow oblong film-coated sustained-release tablet

Package unit

30 tablets (6 tablets/PTP x 5)